156 related articles for article (PubMed ID: 35176116)
1. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.
van der Meulen MP; Toes-Zoutendijk E; Spaander MCW; Dekker E; Bonfrer JMG; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; van Velthuysen MF; Thomeer MGJ; van Veldhuizen H; de Koning HJ; Lansdorp-Vogelaar I; van Leerdam ME
PLoS One; 2022; 17(2):e0264067. PubMed ID: 35176116
[TBL] [Abstract][Full Text] [Related]
2. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
3. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
[TBL] [Abstract][Full Text] [Related]
4. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
[TBL] [Abstract][Full Text] [Related]
5. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
6. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
7. Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands.
de Klerk CM; van der Vlugt M; Smagge BA; Toes-Zoutendijk E; Lansdorp-Vogelaar I; Dekker E; Bossuyt PM
Prev Med Rep; 2022 Jun; 27():101791. PubMed ID: 35656204
[TBL] [Abstract][Full Text] [Related]
8. Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round.
Stegeman I; de Wijkerslooth TR; Mallant-Hent RC; de Groot K; Stroobants AK; Fockens P; Mundt M; Bossuyt PM; Dekker E
BMC Gastroenterol; 2012 Jun; 12():73. PubMed ID: 22713100
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme.
Kortlever TL; van der Vlugt M; Duijkers FAM; Masclee A; Kraaijenhagen R; Spaander MCW; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E
Br J Cancer; 2023 Sep; 129(5):791-796. PubMed ID: 37468570
[TBL] [Abstract][Full Text] [Related]
10. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
[TBL] [Abstract][Full Text] [Related]
11. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial.
Stoop EM; de Haan MC; de Wijkerslooth TR; Bossuyt PM; van Ballegooijen M; Nio CY; van de Vijver MJ; Biermann K; Thomeer M; van Leerdam ME; Fockens P; Stoker J; Kuipers EJ; Dekker E
Lancet Oncol; 2012 Jan; 13(1):55-64. PubMed ID: 22088831
[TBL] [Abstract][Full Text] [Related]
12. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
13. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
[TBL] [Abstract][Full Text] [Related]
14. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
van der Vlugt M; Grobbee EJ; Bossuyt PM; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Essink-Bot ML; Spaander MC; Dekker E
Br J Cancer; 2017 Jan; 116(1):44-49. PubMed ID: 27923037
[TBL] [Abstract][Full Text] [Related]
15. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
[TBL] [Abstract][Full Text] [Related]
17. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
18. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
[TBL] [Abstract][Full Text] [Related]
19. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
[TBL] [Abstract][Full Text] [Related]
20. Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme.
van de Schootbrugge-Vandermeer HJ; Lansdorp-Vogelaar I; de Jonge L; van Vuuren AJ; Dekker E; Spaander MCW; Ramakers CRB; Nagtegaal ID; van Kemenade FJ; van Leerdam ME; Toes-Zoutendijk E
Eur J Cancer; 2023 Sep; 190():112942. PubMed ID: 37406529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
